orthofix medical - OFIX

OFIX

Close Chg Chg %
10.34 -0.05 -0.48%

Closed Market

10.29

-0.05 (0.48%)

Volume: 324.75K

Last Updated:

Jun 5, 2026, 4:00 PM EDT

Company Overview: orthofix medical - OFIX

OFIX Key Data

Open

$10.33

Day Range

10.20 - 10.58

52 Week Range

9.13 - 16.99

Market Cap

$417.96M

Shares Outstanding

40.42M

Public Float

40.07M

Beta

0.71

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$1.50

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

534.62K

 

OFIX Performance

1 Week
 
11.00%
 
1 Month
 
-11.67%
 
3 Months
 
-18.46%
 
1 Year
 
-6.20%
 
5 Years
 
-74.79%
 

OFIX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About orthofix medical - OFIX

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

OFIX At a Glance

Orthofix Medical, Inc.
3451 Plano Parkway
Lewisville, Texas 75056
Phone 1-214-937-2000 Revenue 822.31M
Industry Medical Specialties Net Income -92,192,000.00
Sector Health Technology 2025 Sales Growth 2.854%
Fiscal Year-end 12 / 2026 Employees 1,605
View SEC Filings

OFIX Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 0.73
Price to Book Ratio 1.342
Price to Cash Flow Ratio 18.00
Enterprise Value to EBITDA 81.255
Enterprise Value to Sales 0.874
Total Debt to Enterprise Value 0.283

OFIX Efficiency

Revenue/Employee 512,343.925
Income Per Employee -57,440.498
Receivables Turnover 6.058
Total Asset Turnover 0.943

OFIX Liquidity

Current Ratio 2.445
Quick Ratio 1.434
Cash Ratio 0.499

OFIX Profitability

Gross Margin 67.092
Operating Margin -8.327
Pretax Margin -11.043
Net Margin -11.211
Return on Assets -10.573
Return on Equity -19.344
Return on Total Capital -14.099
Return on Invested Capital -13.74

OFIX Capital Structure

Total Debt to Total Equity 45.296
Total Debt to Total Capital 31.175
Total Debt to Total Assets 23.964
Long-Term Debt to Equity 44.411
Long-Term Debt to Total Capital 30.566
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Orthofix Medical - OFIX

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
460.71M 746.64M 799.49M 822.31M
Sales Growth
-0.81% +62.06% +7.08% +2.85%
Cost of Goods Sold (COGS) incl D&A
131.74M 277.78M 271.04M 270.61M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
29.02M 53.06M 60.06M 77.32M
Depreciation
19.62M 34.16M 41.06M 47.32M
Amortization of Intangibles
9.40M 18.90M 19.00M 30.00M
COGS Growth
+7.26% +110.85% -2.42% -0.16%
Gross Income
328.97M 468.87M 528.45M 551.71M
Gross Income Growth
-3.71% +42.52% +12.71% +4.40%
Gross Profit Margin
+71.41% +62.80% +66.10% +67.09%
2022 2023 2024 2025 5-year trend
SG&A Expense
357.84M 610.63M 606.17M 620.18M
Research & Development
49.07M 80.23M 73.64M 65.85M
Other SG&A
308.78M 530.40M 532.53M 554.33M
SGA Growth
+5.16% +70.64% -0.73% +2.31%
Other Operating Expense
- - - -
-
Unusual Expense
(10.81M) (2.65M) 6.90M 12.96M
EBIT after Unusual Expense
(18.06M) (139.11M) (84.62M) (81.43M)
Non Operating Income/Expense
1.64M (938.00K) (9.63M) 8.11M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
1.29M 8.63M 29.63M 17.49M
Interest Expense Growth
-29.89% +570.11% +243.31% -40.98%
Gross Interest Expense
1.29M 8.63M 29.63M 17.49M
Interest Capitalized
- - - -
-
Pretax Income
(17.71M) (148.68M) (123.88M) (90.81M)
Pretax Income Growth
-31.20% -739.71% +16.68% +26.69%
Pretax Margin
-3.84% -19.91% -15.49% -11.04%
Income Tax
2.04M 2.72M 2.12M 1.38M
Income Tax - Current - Domestic
1.15M 17.00K (590.00K) 534.00K
Income Tax - Current - Foreign
578.00K 2.12M 829.00K 625.00K
Income Tax - Deferred - Domestic
67.00K 1.16M 1.57M 773.00K
Income Tax - Deferred - Foreign
247.00K (581.00K) 311.00K (550.00K)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(19.75M) (151.40M) (126.00M) (92.19M)
Minority Interest Expense
- - - -
-
Net Income
(19.75M) (151.40M) (126.00M) (92.19M)
Net Income Growth
+48.54% -666.60% +16.78% +26.83%
Net Margin Growth
-4.29% -20.28% -15.76% -11.21%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(19.75M) (151.40M) (126.00M) (92.19M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(19.75M) (151.40M) (126.00M) (92.19M)
EPS (Basic)
-0.9848 -4.1219 -3.3041 -2.3279
EPS (Basic) Growth
+49.47% -318.55% +19.84% +29.55%
Basic Shares Outstanding
20.05M 36.73M 38.13M 39.60M
EPS (Diluted)
-0.9848 -4.1219 -3.3041 -2.3279
EPS (Diluted) Growth
+49.47% -318.55% +19.84% +29.55%
Diluted Shares Outstanding
20.05M 36.73M 38.13M 39.60M
EBITDA
151.00K (88.70M) (17.66M) 8.85M
EBITDA Growth
-99.51% -58,840.40% +80.09% +150.12%
EBITDA Margin
+0.03% -11.88% -2.21% +1.08%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 16.25
Number of Ratings 5 Current Quarters Estimate -0.41
FY Report Date 06 / 2026 Current Year's Estimate -1.215
Last Quarter’s Earnings -0.52 Median PE on CY Estimate N/A
Year Ago Earnings -2.33 Next Fiscal Year Estimate -1.01
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 2 2 2 2
Mean Estimate -0.41 -0.28 -1.22 -1.01
High Estimates -0.36 -0.18 -0.95 -0.62
Low Estimate -0.46 -0.37 -1.48 -1.40
Coefficient of Variance -17.25 -48.85 -30.85 -54.61

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 3
OVERWEIGHT 0 0 0
HOLD 2 2 2
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Orthofix Medical - OFIX

Date Name Shares Transaction Value
Apr 21, 2026 Andrés J. Cedrón CLO 59,006 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $12.82 per share 756,456.92

Orthofix Medical in the News